[go: up one dir, main page]

WO2013035053A3 - Procédé inédit de transport de médicaments, facilité par un processus de conjugaison, à travers la barrière hémato-encéphalique - Google Patents

Procédé inédit de transport de médicaments, facilité par un processus de conjugaison, à travers la barrière hémato-encéphalique Download PDF

Info

Publication number
WO2013035053A3
WO2013035053A3 PCT/IB2012/054593 IB2012054593W WO2013035053A3 WO 2013035053 A3 WO2013035053 A3 WO 2013035053A3 IB 2012054593 W IB2012054593 W IB 2012054593W WO 2013035053 A3 WO2013035053 A3 WO 2013035053A3
Authority
WO
WIPO (PCT)
Prior art keywords
brain barrier
blood brain
drugs
facilitated transport
novel conjugation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2012/054593
Other languages
English (en)
Other versions
WO2013035053A2 (fr
Inventor
Uday Saxena
Venkateswarlu Akella
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kareus Therapeutics SA
Original Assignee
Kareus Therapeutics SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kareus Therapeutics SA filed Critical Kareus Therapeutics SA
Publication of WO2013035053A2 publication Critical patent/WO2013035053A2/fr
Anticipated expiration legal-status Critical
Publication of WO2013035053A3 publication Critical patent/WO2013035053A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un agent thérapeutique conjugué de formule I capable de faciliter le transport d'un agent thérapeutique à travers la barrière hémato-encéphalique, ce qui permet d'obtenir une concentration en médicament au niveau du cerveau suffisante pour exercer un effet thérapeutique bienfaisant.
PCT/IB2012/054593 2011-09-09 2012-09-06 Procédé inédit de transport de médicaments, facilité par un processus de conjugaison, à travers la barrière hémato-encéphalique Ceased WO2013035053A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN2536/MUM/2011 2011-09-09
IN2536MU2011 2011-09-09
US201161564618P 2011-11-29 2011-11-29
US61/564,618 2011-11-29

Publications (2)

Publication Number Publication Date
WO2013035053A2 WO2013035053A2 (fr) 2013-03-14
WO2013035053A3 true WO2013035053A3 (fr) 2015-08-06

Family

ID=47832672

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2012/054593 Ceased WO2013035053A2 (fr) 2011-09-09 2012-09-06 Procédé inédit de transport de médicaments, facilité par un processus de conjugaison, à travers la barrière hémato-encéphalique

Country Status (1)

Country Link
WO (1) WO2013035053A2 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050070608A1 (en) * 2003-08-29 2005-03-31 Julius Remenar Pharmaceutical compositions and method of using levodopa and carbidopa
US20080249058A1 (en) * 2007-04-05 2008-10-09 Erik Roberson Agents that reduce neuronal overexcitation
US20100298268A1 (en) * 2007-12-28 2010-11-25 Ann Hsu Controlled release formulations of levodopa and uses thereof
US20110097347A1 (en) * 2008-07-11 2011-04-28 Uday Saxena Niacin compositions for reduction of amyloid beta peptide 42 (abeta 42) production and for treatment of alzheimer's disease (ad)
US20110098278A1 (en) * 2009-07-23 2011-04-28 Shire Llc Galantamine amino acid and peptide prodrugs and uses thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050070608A1 (en) * 2003-08-29 2005-03-31 Julius Remenar Pharmaceutical compositions and method of using levodopa and carbidopa
US20080249058A1 (en) * 2007-04-05 2008-10-09 Erik Roberson Agents that reduce neuronal overexcitation
US20100298268A1 (en) * 2007-12-28 2010-11-25 Ann Hsu Controlled release formulations of levodopa and uses thereof
US20110097347A1 (en) * 2008-07-11 2011-04-28 Uday Saxena Niacin compositions for reduction of amyloid beta peptide 42 (abeta 42) production and for treatment of alzheimer's disease (ad)
US20110098278A1 (en) * 2009-07-23 2011-04-28 Shire Llc Galantamine amino acid and peptide prodrugs and uses thereof

Also Published As

Publication number Publication date
WO2013035053A2 (fr) 2013-03-14

Similar Documents

Publication Publication Date Title
WO2013170068A3 (fr) Modulateurs du transport nucléaire et leurs utilisations
MX2014009757A (es) Derivados de isoindolina, composiciones farmaceuticas que los contienen y su uso en terapia.
EP3682875A3 (fr) Méthodes de traitement du syndrome métabolique pédiatrique
EP2702994A3 (fr) Procédés d'administration d'une thérapie par pirfénidone
IN2012DN06720A (fr)
PH12014500386A1 (en) Combination treatment for hepatitis c
IL232251B (en) Pharmaceutical combination for use in the treatment of type 2 diabetes patients
PH12015502628B1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of disease
EP2894985A4 (fr) Profils d'administration de médicaments programmables de bactéries ciblées par une tumeur
MX2015016344A (es) Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
EA201401028A1 (ru) Фармацевтическая композиция, содержащая эмпаглифлозин и лекарственное средство от ожирения
MX344238B (es) Compuestos de tetrazol y métodos para preparar y usar los mismos.
MX356728B (es) Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.
EP2493459A4 (fr) Dispositifs d'administration de médicaments par voie oculaire
WO2011127333A3 (fr) Composés pour le traitement d'une maladie, pour l'administration, et pour des compositions pharmaceutiques
EP2773379A4 (fr) Administration sous-cutanée de conjugués polymères d'agents thérapeutiques
MY168212A (en) A new therapeutical composition containing apomorphine as active ingredient
MX2015004362A (es) Derivados de ketamina.
WO2014107730A3 (fr) Utilisation de conjugués d'acides gras et de niacine en vue du traitement de maladies
EP3238724A3 (fr) Suppresseurs chimiques de la neurotoxicité dans des maladies synucléinopathiques
ZA201400646B (en) Topical ophthalmological pharmaceutical composition containing regorafenib
EP2898912A4 (fr) Instrument d'administration de médicament
ZA201404068B (en) The use of silver(i) complexes as active pharmaceutical ingredients (api's) iincluding anticancer agents
MX2015014905A (es) Compuestos de pirazino - [1,2-a] indol, su preparacion y su uso en medicamentos.
MX366309B (es) Composicion farmaceutica para el tratamiento de inflamacion y dolor.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12829456

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12829456

Country of ref document: EP

Kind code of ref document: A2